About IRRAS
IRRAS is a company based in Stockholm (Sweden) founded in 2012 was acquired by ClearPoint Neuro in November 2025. IRRAS has raised $11.25 million across 2 funding rounds from investors including ClearPoint Neuro, Serendipity Innovations and Invest Stockholm. IRRAS offers products and services including IRRA flow, Hummingbird Quad, Hummingbird Solo, and Hummingbird ICP Control Module. IRRAS operates in a competitive market with competitors including CereVasc, Tissuemed, Longeviti, Aqueduct Critical Care and NeuroDx, among others.
- Headquarter Stockholm, Sweden
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Irras Ab
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$11.25 M (USD)
in 2 rounds
-
Latest Funding Round
$11.25 M (USD), Series A
May 11, 2016
-
Investors
ClearPoint Neuro
& 2 more
-
Employee Count
Not available
-
Acquired by
ClearPoint Neuro
(Nov 06, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of IRRAS
IRRAS offers a comprehensive portfolio of products and services, including IRRA flow, Hummingbird Quad, Hummingbird Solo, and Hummingbird ICP Control Module.
Provides automated irrigation and continuous pressure monitoring for drainage.
Offers quad ICP monitoring with drainage for advanced neuromonitoring.
Delivers solo ICP monitoring with accurate parenchymal measurements.
Enables rezeroing and multimodal monitoring through a single access point.
People of IRRAS
Unlock access to complete
Unlock access to complete
Funding Insights of IRRAS
IRRAS has successfully raised a total of $11.25M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $11.25 million completed in May 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in IRRAS
IRRAS has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include ClearPoint Neuro, Serendipity Innovations and Invest Stockholm.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Promotes investment, business setup, and talent recruitment in Stockholm region.
|
Locked | Locked | Locked | |
|
Software and hardware solutions for MRI-guided surgical planning are provided.
|
Locked | Locked | Locked |
Investor details for IRRAS
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IRRAS
Investment portfolio details for IRRAS
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - IRRAS
Detailed financials for IRRAS
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Irras Comparisons
Peer comparison for IRRAS
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of IRRAS
IRRAS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CereVasc, Tissuemed, Longeviti, Aqueduct Critical Care and NeuroDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
eShunt device is developed for communicating hydrocephalus treatment.
|
|
| Locked | Locked | Locked |
Bioadhesive films are developed to seal leaks in surgical procedures.
|
|
| Locked | Locked | Locked |
Implantable neurosurgical devices are developed for cranial defect correction.
|
|
| Locked | Locked | Locked |
Novel products to manage Cerebral Spinal Fluid (CSF) pressure
|
|
| Locked | Locked | Locked |
Medical devices for assessing shunt function in hydrocephalus patient.
|
Detailed competitors of IRRAS
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Irras
Complete news archive for IRRAS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IRRAS
IRRAS was founded in 2012 and raised its 1st funding round 1 year after it was founded.
IRRAS is headquartered in Stockholm, Sweden.
Will Martin is the current CEO of IRRAS.
IRRAS is a funded company, having raised a total of $11.25M across 2 funding rounds to date.
IRRAS develops devices for fluid control and management for several brain pathologies, CNS therapeutic applications, and procedures. Its products include instruments and catheters for the clinical, monitoring and surgical applications for brain pathology indications. Its flagship products IRRAflow provides, dynamic control of brain fluids, for irrigation and aspiration, precise infusion of fluids and intracranial pressure monitoring. It can be used for the treatments for infections and malignant tumors such as Ventriculitis, Meningitis, Abscesses and Osteomyelitis of the skull, and others.
IRRAS's top competitors include CereVasc, Tissuemed and Aqueduct Critical Care.
IRRAS offers IRRA flow, Hummingbird Quad, Hummingbird Solo, and Hummingbird ICP Control Module.
IRRAS has 3 investors. Key investors include ClearPoint Neuro, Serendipity Innovations, and Invest Stockholm.